A prognostic tool estimates the probability of progression from an asymptomatic, precancerous plasma cell disorder to active multiple myeloma. These tools utilize various clinical and laboratory parameters to stratify individuals based on their risk. For instance, a model may incorporate factors like the percentage of plasma cells in the bone marrow, the presence of specific proteins in the serum, and the degree of immune dysfunction to generate a risk score.
These assessments are valuable in clinical decision-making because they aid in identifying individuals who might benefit from earlier intervention strategies. Identifying high-risk individuals allows for closer monitoring and potential participation in clinical trials evaluating early treatment approaches. The development and refinement of these tools have evolved alongside advancements in understanding the biological and clinical heterogeneity of plasma cell disorders, leading to more personalized risk assessments.
